Linda Estefania Cordero Velez

Linda Estefania Cordero Velez

Auto-generated profile, based on publicly available information

Linda Estefania Cordero Velez

Universidad del Azuay, Cuenca, Ecuador

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2026 in Pediatric Nephrology
Verified
Journal Article
Open access
PDF file
Candela RomanoCandela Romano
Candela Romano
LALisyareli Salazar Arriaga
Lisyareli Salazar Arriaga
LVLinda Estefania Cordero Velez
Linda Estefania Cordero Velez
ADAlexandra Melendez Delgado
Alexandra Melendez Delgado
TDTatiana Alexandra Moreno Díaz
Tatiana Alexandra Moreno Díaz
EMErnesto Calderon Martinez
Ernesto Calderon Martinez
Background: Corticosteroids remain the cornerstone of therapy for steroid-sensitive nephrotic syndrome (SSNS), yet the optimal dosing strategy, single daily versus divided doses, remains uncertain. Methods: We conducted a systematic review of studies comparing once-daily and divided-dose prednisolone in children with SSNS. Three randomized controlled trials and one non-randomized study were included, enrolling a total of 288 patients. Primary outcomes were time to remission and relapse frequency; secondary outcomes included hypothalamic–pituitary–adrenal (HPA) axis suppression and adverse events. Results: Overall, remission rates were comparable between single and divided dosing. In relapse settings, one trial showed faster remission with split dosing (by 1–2 days), though without differences in relapse frequency or safety. In first-episode disease, single daily dosing was associated with less HPA axis suppression and a longer time to first relapse. Adverse event profiles were similar across regimens. Conclusions: Single-dose and split-dose prednisolone regimens demonstrate comparable remission efficacy in children with SSNS. Divided dosing may shorten remission by 1–2 days during relapse episodes, but this small benefit must be weighed against the greater HPA-axis suppression observed with multi-dose schedules. Given the heterogeneity and small sample sizes of available trials, the current evidence remains insufficient to establish superiority. Larger multicenter RCTs with standardized protocols and longer follow-up are needed to provide more definitive guidance. Graphical A higher resolution version of the Graphical abstract is available as Supplementary information